ScreenerHero

ERAS Erasca, Inc.

NAS · US · Healthcare · Biotechnology · erasca.com
14.12USD-1.26%Mkt Cap: 4.94B $P/E: —

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap4.94B USD
Enterprise Value4.78B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-124.55M USD
Revenue/Share—
Last Price14.12 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees103
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-22.95
PEG—
EV/EBITDA-32.34
EV/Revenue—
P/S—
P/B12.35
EPS (TTM)-0.92
EPS (Forward)-0.62
52W Range
1.77555% of range24.28
52W High24.28 USD
52W Low1.775 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-38.30%
ROA-31.44%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-95.45M USD
CapEx (TTM)9.63M USD
FCF Margin—
FCF Yield-4.26%
Net Debt-224.02M USD
Net Debt/EBITDA1.52
Balance Sheet
Debt/Equity0.14
Current Ratio8.29
Quick Ratio8.08
Book Value/Sh1.16 USD
Cash/Share0.77 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)24.11 USD
Upside (mean)+70.8%
Target Range20.00 USD – 33.00 USD
20.00+70.8% to mean33.00
# Analysts9
Ownership
Shares Out.349.76M
Float255.21M
Insiders5.96%
Institutions86.18%
Short Interest
Short Ratio8.6d
Short % Float10.45%
Short % Out.9.45%
Shares Short33.04M
Short (prev mo.)30.85M
Technical
SMA 5016.82 (-16.1%)
SMA 20014.04 (+0.6%)
Beta0.62
S&P 52W Chg16.45%
Avg Vol (30d)4.48M
Avg Vol (10d)4.38M
Technical Indicators
RSI (14)37.0
MACD-0.7158
MACD Signal-0.7548
MACD Hist.+0.0390
BB Upper16.60 USD
BB Middle14.99 USD
BB Lower13.39 USD
BB Width21.39%
ATR (14)0.9995 USD
Vol Ratio (20d)0.81x